1.上海中医药大学附属龙华医院呼吸疾病研究所,上海 200032
邱磊,男,29岁,博士,主治医师。研究方向:中医药防治呼吸系统疾病的临床与基础研究。
鹿振辉,E-mail:Dr_luzh@shutcm.edu.cn
扫 描 看 全 文
邱磊,杨小钰,陈佳骏,等.桑白皮汤联合西医常规治疗支气管扩张症痰热壅肺证疗效观察[J].北京中医药,2023,42(8):819-823.
QIU Lei,YANG Xiao-yu,CHEN Jia-jun,et al.Observation on curative effect of Sangbaipi Decoction combined with routine western medicine in treating bronchiectasis with phlegm-heat obstructing lung syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(08):819-823.
邱磊,杨小钰,陈佳骏,等.桑白皮汤联合西医常规治疗支气管扩张症痰热壅肺证疗效观察[J].北京中医药,2023,42(8):819-823. DOI: 10.16025/j.1674-1307.2023.08.002.
QIU Lei,YANG Xiao-yu,CHEN Jia-jun,et al.Observation on curative effect of Sangbaipi Decoction combined with routine western medicine in treating bronchiectasis with phlegm-heat obstructing lung syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(08):819-823. DOI: 10.16025/j.1674-1307.2023.08.002.
目的,2,观察桑白皮汤联合西医常规治疗支气管扩张症(简称“支扩”)痰热壅肺证的临床疗效。,方法,2,选择2019年1月—2022年12月就诊于上海中医药大学附属龙华医院门诊的支扩患者62例,采用简单随机方法按照1∶1比例分为中药组和对照组。中药组接受西医基础治疗联合中药桑白皮汤颗粒治疗,对照组仅接受西医基础治疗,疗程1个月。对比2组治疗结束后3个月内出现的支扩急性加重情况,治疗前及治疗后3个月末圣乔治呼吸问卷(SGRQ)评分及改善值,肺功能指标及改善值,监测不良事件和实验室指标。,结果,2,治疗后3个月内,中药组、对照组急性加重分别为4、5例,差异无统计学意义(,P,>,0.05)。治疗后3个月末,2组SGRQ评分(症状、活动、心理评分和总分)均较治疗前降低(,P<,0.05),中药组SGRQ评分改善值均高于对照组(,P<,0.05)。治疗后3个月末,2组肺功能参数(FEV1、FVC、FEV1/FVC)均较治疗前提高,但组内比较差异无统计学意义(,P,>,0.05);中药组肺功能指标改善值与对照组比较,差异无统计学意义(,P,>,0.05)。中药组不良事件发生率为32.3%(10/31),其中腹泻4例、腹胀3例和恶心3例。对照组不良事件发生率为35.5%(11/31),其中腹泻5例、腹胀2例和恶心4例。2组比较差异无统计学意义(χ,2,=0.072,,P,>,0.05)。,结论,2,桑白皮汤联合西医常规治疗支扩痰热壅肺证能够显著改善患者的临床症状、活动能力、耐力和心理状态,且安全性良好。
Objective,2,To analyze the therapeutic effect of Sangbaipi Decoction on bronchiectasis with phlegm-heat obstructing the lung syndrome.,Methods,2,A total of 62 patients with bronchiectasis with phlegm-heat obstructing the lung syndrome, who visited Longhua Hospital Affiliated to the Shanghai University of Traditional Chinese Medicine from January 2019 to December 2022, were randomly divided into a traditional Chinese medicine (TCM) group(,n,=31) and a control group(,n,=31). The control group received routine western medicine treatment alone, and the TCM,group received western medicine combined with Sangbaipi Decoction Granules for one month. The proportion of acute exacerbation of bronchiectasis within 3 months after treatment, the pulmonary function indicators before and after treatment, and the St. George's Respiratory Questionnaire (SGRQ) before and after treatment were compared between the two groups, and the adverse events and laboratory indicators were recorded simultaneously.,Results,2,Within 3 months after treatment, there were 4 cases of acute exacerbation in TCM group and 5 cases in control group, with no statistical significance(,P,>,0.05). At the end of 3 months after treatment, the SGRQ scores (symptoms, activity, psychological score and total score) in both groups were lower than those before treatment(,P,<,0.05), and the SGRQ scores in TCM group were higher than those in the control group(,P,<,0.05).At the end of 3 months after treatment, the pulmonary function parameters (FEV1,FVC,FEV1/FVC) of the two groups were all improved compared with those before treatment, but there was no statistical difference between the two groups(,P,>, 0.05). Compared with the control group, there was no significant difference in the improvement of pulmonary function indexes in the Chinese medicine group(,P,>,0.05). The incidence of adverse events in TCM group was 32.3%(10/31), including 4 cases of diarrhea, 3 cases of abdominal distension and 3 cases of nausea. The incidence of adverse events in the control group was 35.5%(11/31), including 5 cases of diarrhea, 2 cases of abdominal distension and 4 cases of nausea. There was no significant difference between the two groups (,χ,2,=0.072,,P,>,0.05).,Conclusion,2,Conventional western medicine treatment combined with Sangbaipi Decoction can significantly improve the clinical symptoms, activity/endurance, and psychological state inpatients with bronchiectasis of phlegm-heat obstructing the lung syndromewith good safety.
支气管扩张症痰热壅肺证桑白皮汤辨证论治
Bronchiectasissyndrome of phlegm-heat obstructing the lungSangbaipi Decoctionsyndrome differentiation and treatment
蔡柏蔷,何权瀛,高占成,等.成人支气管扩张症诊治专家共识(2012版)[J].中华危重症医学杂志(电子版),2012,5(5):315-328.
HILL AT, SULLIVAN AL, CHALMERS JD, et al. British Thoracic Society guideline for bronchiectasis in adults[J]. BMJ Open Respir Res, 2018,5(1):e348.
LIN JL, XU JF, QU JM. Bronchiectasis in China[J]. Ann Am Thorac Soc, 2016,13(5):609-616.
王香英,李素云.中医药辨证治疗支气管扩张症的现状概述[J].中医临床研究,2020,12(2):143-145.
国家中医药管理局. 关于发布《古代经典名方目录(第一批)》的通知[EB/OL].(2018-04-13)[2023-04-07] http://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5429153.htmhttp://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5429153.htm.
李建生,王至婉,谢洋,等.支气管扩张症中医证候诊断标准(2019版)[J].中医杂志,2020,61(15):1377-1380.
支气管扩张症专家共识撰写协作组,中华医学会呼吸病学分会感染学组.中国成人支气管扩张症诊断与治疗专家共识[J].中华结核和呼吸杂志,2021,44(4):311-321.
O'DONNELL AE. Bronchiectasis:A clinical review[J]. N Engl J Med, 2022,387(6):533-545.
CHALMERS JD, HAWORTH CS, METERSKY ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis[J]. N Engl J Med, 2020,383(22):2127-2137.
张惠勇,李欣,倪伟,等.支气管扩张证中医辨证分型规律的研究[J].上海中医药杂志,2005,39(1):16-18.
唐雪春,陈小燕.150例支气管扩张住院患者中医证候分布规律的回顾性研究[J].辽宁中医杂志,2008,35(8):1157-1158.
房波,赵刚.苇金消痈汤加减辅助治疗支气管扩张急性加重期痰热壅肺证的临床分析[J].中国实验方剂学杂志,2016,22(15):194-198.
狄冠麟,朱振刚,郑延龙.清金化痰汤加减治疗支气管扩张症急性加重期痰热蕴肺证的临床观察[J].中国实验方剂学杂志,2020,26(1):98-103.
邱磊,张少言,岑俊,等.中医药治疗支气管扩张症研究进展与思考[J].中国中医药信息杂志,2023,30(4):163-168.
邱磊,杨铭,张少言等.基于现代文献和数据挖掘探讨支气管扩张症的中医组方用药规律[J].结核与肺部疾病杂志,2020,1(4):233-239.
邱磊,徐皓,杨小钰,等.基于网络药理学探讨桑白皮汤治疗支气管扩张症的潜在作用机制[J].实用中医内科杂志,2023,37(7):9-12,176-179.
WILSON CB, JONES PW, O'LEARY CJ, et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis[J]. Am J Respir Crit Care Med, 1997,156(2 Pt 1):536-541.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构